Teclistamab in Relapsed or Refractory Multiple Myeloma

Moreau, P; Garfall, AL; van de Donk, NWCJ; Nahi, H; San-Miguel, JF; Oriol, A; Nooka, AK; Martin, T; Rosinol, L; Chari, A; Karlin, L; Benboubker, L; Mateos, MV; Bahlis, N; Popat, R; Besemer, B; Martinez-Lopez, J; Sidana, S; Delforge, M; Pei, LX; Trancucci, D; Verona, R; Girgis, S; Lin, SXW; Olyslager, Y; Jaffe, M; Uhlar, C; Stephenson, T; Van Rampelbergh, R; Banerjee, A; Goldberg, JD; Kobos, R; Krishnan, A; Usmani, SZ

Moreau, P (通讯作者),Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France.

NEW ENGLAND JOURNAL OF MEDICINE, 2022; 387 (6): 495

Abstract

BACKGROUND Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation ant......

Full Text Link